Deals Shaping the Medical Industry (2/2012)
Executive Summary
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
You may also be interested in...
Affibody And UCB Eye Humira’s Weak Spot In Hidradenitis Suppurativa
The rival firms are advancing separate biologic candidates that target IL-17 in a bid to treat the more than 60% of hidradenitis suppurativa patients who remain uncontrolled on AbbVie’s Humira, with recent trial readouts showing promise.
Pharma Giants Urge Biotechs To Get In Touch As Early As Possible
Although money is too tight to mention for some biotechs, last year the value of preclinical partnerships actually went up and Switzerland’s big two pharma players are on the lookout for more.
Rare Disease Body Wants EU Legislative Overhaul To Address Orphan Definitions & Incentives
Eurordis has welcomed some parts of the leaked proposals for overhauling the EU medicines legislation, but it has a number of concerns, including the future role of patient representatives if the European Medicines Agency’s committee structure is slimmed down as planned.